Latest Breaking News On - Avego bioscience capital - Page 1 : vimarsana.com

Ribon Therapeutics, a Cambridge, Mass.-based clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, closed a $65m financing. The round was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation – JJDC, Inc., Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group. The company will use the proceeds to support the clinical development of its novel precision medicine candidates. Led by Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to di

United kingdomOsage university partnersBristol myers squibbNovartis venture fundColumn groupJjdc incRibon therapeuticsDeerfield managementAvego bioscience capitalGoogle venturesMonashee investment managementPeregrine venturesAbbvie venturesEuclidean capitalJohnson innovationTakeda ventures